Agile Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Agile Therapeutics

30/03/2022 22:50

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 15 cents per share.
    * Revenue rose 102.1% to $1.51 million from a year ago; 
analysts
expected $1.51 million. 
    * Agile Therapeutics Inc's reported EPS for the quarter was
a loss
of 20 cents​.
    * The mean earnings estimate of analysts had fallen by
about 15.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Agile Therapeutics Inc shares had fallen by 46.8% this
quarter.
    * The company reported a quarterly loss of $23.36 million.
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $2.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 30 at 09:49 p.m.  ​All
figures in US dollars unless otherwise stated